Anzeige
Mehr »
Mittwoch, 03.09.2025 - Börsentäglich über 12.000 News
Geheime Uran-Aktie: Ist das der historische "New Deal"-Moment für amerikanischen Uransektor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 867003 | ISIN: JP3546800008 | Ticker-Symbol: TUO
Tradegate
02.09.25 | 10:42
15,300 Euro
-0,65 % -0,100
Branche
Gesundheitswesen
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
TERUMO CORPORATION Chart 1 Jahr
5-Tage-Chart
TERUMO CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
15,10015,50011:23
15,10015,40010:09
PR Newswire
153 Leser
Artikel bewerten:
(0)

Terumo Neuro Unveils New SOFIA Flow 88 Neurovascular Aspiration Catheter Data from EMEA Demonstrating Strong Performance

Real-World EMEA Physician Preference Data1 Demonstrates the SOFIA Flow 88 Aspiration Catheter's Trackability, Navigation, and Overall Performance in Stroke Procedures

MARSEILLE, France, Sept. 3, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world EMEA physician preference data for the SOFIA Flow 88 Aspiration Catheter at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) 17th Annual Congress. The data-presented publicly for the first time -demonstrates strong performance compared to other aspiration catheters1 in key performance metrics such as trackability, navigation and overall physician-rated experience.

SOFIA Flow 88 Neurovascular Aspiration Catheter Data for EMEA Demonstrating Strong Performance

Collected from 70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed:

  • 83% of physicians reported that SOFIA Flow 88 catheter reliably reached the target location-even in anatomically challenging cases, with 76% of procedures in ICA-T or beyond
  • 100% of physicians rated SOFIA Flow 88 catheter "Same" or "Better" than SOFIA Plus 6F for ease of trackability to target vessel location
  • 92% of physicians rated the SOFIA Flow 88 catheter as "Same", "Better" or "Much Better" than alternative aspiration catheters overall

"The SOFIA Flow 88 Neurovascular Aspiration Catheter represents a meaningful advancement in mechanical thrombectomy therapy across EMEA," said Carsten Schroeder, President and CEO of Terumo Neuro. "Its super bore design maximizes aspiration and minimizes flow disruption while delivering exceptional support. It enables physicians to navigate even the most tortuous anatomies in an atraumatic fashion. We're proud that physician preference data so clearly underlines SOFIA Flow 88 catheter's strong performance. It reinforces the SOFIA catheter family's reputation as 'best in class' for trackability, navigation and overall performance."

The SOFIA Flow 88 Neurovascular Aspiration Catheter was commercially launched in the EMEA on June 2, 2025, as the latest addition to Terumo Neuro's global stroke portfolio. Engineered for reliable trackability, proximal stability, and vessel-friendly flexibility, the SOFIA Flow 88 catheter is designed to optimize physician control and integration into a variety of aspiration and combination strategies.

The physician preference data unveiled at ESMINT builds on results from the U.S.-based SOFAST data and the European SESAME Study, which demonstrated the safety and efficacy of the SOFIA catheter as a frontline approach in mechanical thrombectomy.

The SOFIA Flow 88 catheter is compatible with the SOFIA Plus 6F Aspiration Catheter and is part of Terumo Neuro's fully integrated stroke solution, including:

  • ERIC Retrieval Device - For thrombus control and procedural versatility
  • BOBBY Balloon Guide Catheter - Offering reliable2 flow arrest with next-gen balloon technology
  • WEDGE and HEADWAY Microcatheters - Designed for navigation support and access efficiency
  • TRAXCESS Guidewires - Soft-tip wires built for challenging anatomies

About Terumo Neuro

We're in business to create and deliver innovations that redefine what's possible in neurovascular treatment, meaningfully advancing both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information, please visit www.terumoneuro.com.

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for more than 100 years. Based in Tokyo and operating globally, Terumo employs over 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company began as a Japanese thermometer manufacturer and now offers an extensive portfolio-from vascular intervention and cardio-surgical solutions to blood transfusion, cell therapy technology, and essential clinical products.

Reference

  1. Data on file
  2. Boeckh-Behrens, Tobias & Moehlenbruch, Markus. (2024). P116 The new generation BOBBY balloon guide catheter for mechanical thrombectomies: results of the international prospective STRAIT study. Journal of NeuroInterventional Surgery. 16. A97.1-A97. 10.1136/jnis-2024-ESMINT.152.

Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+1 714 206 9800
christine.mccullough@terumoneuro.com

Terumo Neuro

Info - https://mma.prnewswire.com/media/2762040/Terumo_Neuro_SOFIA_Infographic.jpg

Logo - https://mma.prnewswire.com/media/2613109/Terumo_Neuro___Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/terumo-neuro-unveils-new-sofia-flow-88-neurovascular-aspiration-catheter-data-from-emea-demonstrating-strong-performance-302543901.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.